Sep 23, 2024
Please review the following tables to determine changes to UnitedHealthcare's specialty medical injectable drug programs.
| DRUG NAME | TREATMENT USES |
|---|---|
| PiaSky® (crovalimab-akkz) | Used to treat adult and pediatric patients 13 years of age and older with paroxysmal nocturnal hemoglobinuria and a body weight of at least 40 kg. |
| Yimmugo® (immune globulin intravenous, human-dira) | Used to treat primary humoral immunodeficiency in patients 2 years of age and older. |
| DRUG NAME | THERAPEUTIC CLASS | HCPC CODE(S) | SPECIALTY PHARMACY |
|---|---|---|---|
| Beqvez™ (fidanacogene elaparvovec-dzkt) | Gene Therapy | J3490, J3590, C9399 | Please contact UHC Provider Services at the number on the back of the member ID card for available options |
Disclaimer: Certain specialty medical injectable drug programs and updates will not be implemented at this time for providers practicing in Rhode Island, with respect to certain commercial members, pursuant to the Rhode Island regulation: 230 – RICR-20-30-14. UnitedHealthcare encourages providers practicing in Rhode Island to call in to confirm if prior authorization is required.
Upon prior authorization renewal, the updated policy will apply. UnitedHealthcare will honor all approved prior authorizations on file until the end date on the authorization or the date the member’s eligibility changes. Providers don’t need to submit a new notification/prior authorization request for members who already have an authorization for these medications on the effective date noted above.
Contact your Amwins Connect Regional Sales Manager for more information.
